Faculty News
Professor Aswath Damodaran examines the recent controversies surrounding pharmaceutical company Valeant
—
Excerpt from Bloomberg -- "I think Wall Street's so used to companies feeding analysts performer numbers, Pro Forma EBITDAs. 'Trust us. We're going to add this stuff back. Whether it is restructuring expenses, stock-based compensation, it's going to go away.' And analysts take companies at their word. Companies are going to keep feeding them numbers and Valeant in a sense has taken advantage of that. So when analysts complain about being taken to the cleaners, my response to them is you got what you deserved. Because I think they did exactly what analysts wanted them to do for a while and now it's blowing up in their faces."
Watch the video
Watch the video